London, United Kingdom – 29 November 2023 – Rapid Nutrition PLC (Euronext Growth: ALRPD) is pleased to announce the official commencement of production for its highly anticipated product, Azurene Immunity Booster. Following the recent announcement of the upcoming launch, the company is excited to move forward with the manufacturing phase, bringing us one step closer to offering this innovative health solution to our global community.
The production process is well underway, with our dedicated team working tirelessly to ensure that each batch of Azurene Immunity Boost Traveller meets and exceeds the highest standards of quality, efficacy, and safety. Our commitment to meticulous attention to detail and adherence to stringent protocols underscores our dedication to delivering a product that aligns with our mission to empower travellers and individuals worldwide.
Azurene Immunity Boost Traveller is designed to be a game-changer in the realm of supporting immune health, featuring a potent blend of carefully selected ingredients backed by cutting-edge research to reduce the occurrence of mild upper respiratory tract infections, as well as sore throat, while travelling. As we progress through the production phase, we look forward to sharing more details about the official launch date, distribution channels, and how individuals can be among the first to experience the benefits of Azurene.
“We are thrilled to announce the commencement of production for Azurene Immunity Boost Traveller,” said Simon St Ledger, CEO. “This milestone represents a significant step forward in our ongoing commitment to providing innovative health solutions to our community. We believe that Azurene will make a positive impact on the lives of individuals seeking a proactive approach to immune health.”
Rapid Nutrition PLC will continue to provide regular updates on the progress of Azurene Immunity Booster Traveller production and other related milestones.
For more information and to stay informed about the official product launch, please visit http://rnplc.com
About Rapid Nutrition
Rapid Nutrition is a leading health and wellness company committed to providing innovative solutions for a healthier world. With a focus on research-backed formulas, we empower individuals to optimize their well-being and face life’s challenges with confidence.
Investor Relations Contact:
Disclaimer
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and or otherwise that involve risks, uncertainties and assumptions that could cause Rapid Nutrition PLCs actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. Rapid Nutrition PLC has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Rapid Nutrition PLC undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
This media information does not constitute an offer to sell, or a solicitation of an offer to buy, any securities. This information does not constitute an offering prospectus within the meaning within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 of June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71 or a listing prospectus within the meaning of the listing rules of the Euronext Exchange or OTC Markets. The media release is in accordance with International Reporting Standard: Rule 12g3-2(b) under the Securities Exchange Act (‘Rule 12g3-2(b)’) permits non-U.S. companies with securities listed primarily on a Qualified Foreign Exchange to make publicly available to U.S investors in English the same information that is made publicly available in their home countries as an alternative to SEC reporting Exchange Act Rule 12g3-2(b).